EUCTR2007-003560-21-DE进行中（未招募）不适用
Prospective multicenter dose finding phase II pilot trial to evaluate efficacy and safety of treatment with Lenalidomide puls R-CHOP21 (LR-CHOP21) for elderly patients with untreated Diffuse Large B-Cell Lymphoma (DLBCL) - REAL07 Revlimid in Elderly Aggressive Lymphoma
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie Onlus (GIMURELL)0 个研究点目标入组 49 人开始时间: 2010年5月11日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 49
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Understand and voluntarily sign an informed consent form
- •2. Able to adhere to the study visit schedule and other protocol requirements
- •3. Histologic subtypes as follows:
- •CD20 positive Diffuse large B-Cell lymphoma
- •CD20 positive Follicular grade IIIb
- •4. Age 60-80
- •5. Untreated patients. In patients with bulky mass or systemic symptoms or compressive disease or rapidly progressive adenopathies a pre-study treatment is allowed with steroids and/or a single dose of Vincristine 1.4 mg/mq (max 2) in the seven days prior the start of the study treatment
- •6. Measurable and/or evaluable disease
- •7. Ann Arbor stage II, III, IV
- •8. International Prognostic Index at low-intermediate, intermediate-high, high risk (2/3/4-5)
- •9. Adequate haematological counts: ANC > 1.5 x 109/L and platelet count > 75 x 109/L unless due to bone marrow involvement
- •10. Conjugated bilirubin up to 2 x UNL.
- •11. Alkaline phosphatase and transaminases up to 2 x UNL.
- •12. Creatinine clearance > 50 ml/min.
- •13. HIV negativity
- •14. HCV negativity
- •15. HBV negativity or patients with HBVcAb +, HbsAg -, HBs Ab+/- with HBV-DNA negative
- •16. Cardiac ejection fraction (MUGA scan or echocardiography) > 45%
- •17. Non peripheral neuropathy or CNS disease. Non testicular Lymphoma
- •18. Life expectancy > 6 months.
- •19. Performance status < 2 according to ECOG scale.
- •20. Comprehensive geriatric assessment (CGA) as outlined in Appendix 15 showing absence of any impairment in activity of daily living (ADL), of any condition defining a geriatric syndrome, and of any grade 4 comorbidity or of more than three grade 3 comorbidities according to CIRS-G scale
- •21. Disease free of prior malignancies for = 3 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma insitu” of the cervix or breast
- •22. Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; and 3) for at least 28 days after discontinuation from the study. The two methods of reliable contraception must include one highly effective method (i.e. intrauterine device (IUD), hormonal [birth control pills, injections, or implants], tubal ligation, partner’s vasectomy) and one additional effective (barrier) method (i.e. latex condom, diaphragm, cervical cap). FCBP must be referred to a qualified provider of contraceptive methods if needed.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Lymphoblastic Lymphoma
- •2. Burkitt Lymphoma
- •3. Non Hodgkin lymphoma CD 20 negative
- •4. Mantle Cell Lymphoma
- •5. Follicular Non Hodgkin Lymphoma grade I-II-IIIa
- •6. Primitive mediastinal diffuse large B cell lymphoma with only mediastinal involvement
- •7. International Prognostic Index at low risk (1)
- •8. Has known or suspected hypersensitivity or intolerance to Rituximab
- •9. History of evolutive malignancy within the last 3 years other than squamous cell and basal cell carcinoma of the skin or carcinoma in situ of the cervix or breast
- •10. Extensive radiation therapy, systemic chemotherapy, or other antineoplastic therapy before enrollment within 3 years before the start of treatment
- •11. Exposure to Rituximab prior to study entry
- •12. Have received an experimental drug or used an experimental medical device within 4 weeks before the planned start of treatment. Concurrent participation in non-treatment studies is allowed, if it will not interfere with participation in this study
- •13. CNS disease (meningeal and/or brain involvement by lymphoma) or Testicular involvement
- •14. DVT in the last year
- •15. History of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances
- •16. Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months before first dose of study drug
- •17. Uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrollment, New York Heart Association (NYHA) Class III or IV heart failure (Attachment 5, NYHA Classification of Cardiac Disease), uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis
- •18. Creatinine clearance < 50 ml/min
- •19. Presence of major neurological disorders
- •20. HIV positivity
- •21. HBV positivity with the exception of patients with HBVcAb +, HbsAg -, HBs Ab+/- with HBV-DNA negative
- •22. HCV positivity
- •23. Active opportunistic infection
- •24. Comprehensive geriatric assessment (CGA) as outlined in Appendix 15 showing presence of any impairment in activity of daily living (ADL), of any condition defining a geriatric syndrome, and of any grade 4 comorbidity or of more than three grade 3 comorbidities according to CIRS-G scale
- •25. Any other co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent
研究者
相似试验
招募中
2 期
A multicenter phase 1/2 study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas2024-514826-22-00OSE Immunotherapeutics70
进行中（未招募）
不适用
MULTICENTRIC PROSPECTIVE DOSE-FINDING AND PHASE II STUDY WITH ORAL TOPOTECAN IN ADVANCED SMALL-CELL LUNG CANCER (SCLC) PATIENTS RECURRENT AFTER A FIRST LINE THERAPY - SCLCEUCTR2009-015296-26-ITAZIENDA USL 6 LIVORNO ZONA LIVORNESE
已完成
不适用
A phase II, dose ranging, multi-centre study to evaluate the safety and efficacy of combretastatin A4 phosphate for treating subfoveal choroidal neovascularization in subjects with pathologic myopiaMyopiaISRCTN85551991Oxigene (USA)23
进行中（未招募）
Unknown
A Phase IIa, Multi-center, Dose-finding Clinical Trial to Evaluate the Safety, the Efficacy for Prevention of Oral Mucositis and the Pharmacokinetics of MIT-001 in Patients with Lymphoma or Multiple Myeloma Receiving Conditioning Chemotherapy Followed by Autologous Hematopoietic Stem Cell TransplantatioDiseases of the digestive systemKCT0006696MitoImmune Therapeutics60
Unknown
2 期
Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell LymphomaNon Hodgkin LymphomaFollicular LymphomaNCT00907348Fondazione Italiana Linfomi - ETS49